AOD 9604: Growth Hormone Fragment Research Guide

AOD 9604: What the Research Shows

AOD 9604 (Advanced Obesity Drug 9604) is a modified peptide fragment derived from the C-terminal region of human growth hormone, specifically amino acids 176-191. Originally developed by Metabolic Pharmaceuticals in Australia, AOD 9604 was designed to isolate the fat-metabolizing properties of growth hormone while eliminating its growth-promoting and potentially diabetogenic effects.

This selective approach makes AOD 9604 a uniquely valuable research tool for studying lipolysis, adipose tissue metabolism, and body composition — without the confounding effects of IGF-1 elevation and glucose intolerance that accompany full-length GH administration. Proxiva Labs provides research-grade AOD 9604 with third-party verified purity through our testing program.

Growth Hormone Biology and the Lipolytic Fragment

GH’s Dual Nature

Full-length human growth hormone (191 amino acids) has both anabolic and lipolytic properties. Its anabolic effects — mediated largely through IGF-1 — promote tissue growth, cell proliferation, and can impair glucose tolerance. Its lipolytic effects — direct action on adipocytes — promote fat breakdown and oxidation. Researchers in the 1990s discovered that these two functions map to different regions of the GH molecule.

The 176-191 Fragment

The C-terminal fragment spanning amino acids 176-191 retains GH’s lipolytic activity while lacking its growth-promoting effects. AOD 9604 is this fragment with a specific modification: tyrosine residue 182 is stabilized to enhance biological activity and metabolic stability. Crucially, this fragment does not bind the GH receptor in a manner that stimulates IGF-1 production, separating fat metabolism from growth signaling (Ng et al., 2001).

Mechanism of Action

Beta-3 Adrenergic Pathway

AOD 9604 stimulates lipolysis through the beta-3 adrenergic receptor pathway in adipose tissue. This pathway is particularly enriched in visceral (abdominal) fat depots, which may explain AOD 9604’s preferential targeting of metabolically dangerous visceral adiposity.

Lipolysis Without IGF-1

Unlike full-length GH, AOD 9604 does not increase circulating IGF-1 levels. This is a critical distinction because IGF-1 elevation carries risks including insulin resistance, potential tumor growth promotion, and acromegalic features. AOD 9604 achieves fat reduction through a GH-independent mechanism that avoids these concerns.

Lipogenesis Inhibition

Beyond stimulating fat breakdown, AOD 9604 also inhibits lipogenesis — the process of new fat formation. This dual action (increased lipolysis + decreased lipogenesis) creates a more favorable net effect on adipose tissue than either mechanism alone. Research in adipocyte cultures showed dose-dependent inhibition of lipogenic enzyme activity following AOD 9604 treatment (Heffernan et al., 2001).

Fat Metabolism and Lipolysis Research

In Vitro Evidence

Cell culture studies using isolated adipocytes demonstrated that AOD 9604 stimulates lipolysis (glycerol release) in a dose-dependent manner comparable to full-length GH. Importantly, the lipolytic response occurred without the insulin resistance or glucose impairment seen with GH treatment.

Murine Obesity Models

In ob/ob mice (a genetic obesity model), chronic AOD 9604 administration significantly reduced body weight and fat mass without affecting food intake, lean mass, or linear growth. The peptide’s effects were specific to adipose tissue, confirming the selectivity of the 176-191 fragment for lipolytic versus anabolic GH functions (Ng et al., 2001).

Body Composition Studies

Preclinical Data

Multiple preclinical studies have demonstrated AOD 9604’s favorable effects on body composition:

• Significant reduction in body fat percentage without changes in lean mass
• Preferential reduction of visceral adipose tissue (the metabolically most dangerous fat depot)
• No effect on longitudinal bone growth, confirming absence of GH-like anabolic activity
• Maintained bone mineral density despite fat reduction
• No impairment of glucose tolerance or insulin sensitivity

Human Clinical Trials

AOD 9604 advanced through phase 2 clinical trials for obesity. While the primary endpoint (significant weight loss vs placebo) was not met at the studied oral doses, the trials confirmed safety and tolerability in human subjects. The limited efficacy in clinical trials may reflect challenges with oral bioavailability rather than fundamental limitations of the mechanism, as subcutaneous administration showed stronger preclinical effects (Stier et al., 2006).

Cartilage and Osteoarthritis Research

An important secondary research direction for AOD 9604 involves cartilage regeneration and osteoarthritis treatment.

Chondroprotective Effects

Research has demonstrated that AOD 9604 stimulates proteoglycan and collagen synthesis in articular chondrocytes. In animal models of osteoarthritis, intra-articular AOD 9604 injection showed chondroprotective effects including:

• Increased proteoglycan content in articular cartilage
• Stimulation of chondrocyte proliferation
• Reduced cartilage degradation markers
• Improved joint function scores

TGA Recognition

The Australian Therapeutic Goods Administration (TGA) has approved AOD 9604 as a complementary medicine active ingredient, recognizing its safety profile and potential therapeutic applications. This regulatory recognition is notable for a research peptide and reflects the compound’s favorable risk-benefit profile.

Heart Repair and Cardioprotection

Emerging research suggests AOD 9604 may have cardioprotective properties. Preliminary studies indicate the peptide can reduce cardiac inflammation markers and improve cardiac function in models of heart failure. The mechanism may involve beta-3 adrenergic receptor-mediated cardioprotection, as beta-3 receptors in the heart promote nitric oxide production and reduce oxidative stress. This research is still in early stages but represents a promising secondary application.

AOD 9604 vs Full-Length Growth Hormone

AOD 9604 vs Other Fat Loss Peptides

• CJC-1295 + Ipamorelin: Stimulate endogenous GH release, which promotes lipolysis but also elevates IGF-1. More systemic effects vs AOD 9604’s targeted fat metabolism.
• MOTS-C: AMPK-mediated metabolic reprogramming and exercise mimicry. Different mechanism (mitochondrial) vs AOD 9604’s adrenergic pathway.
• Semaglutide/Tirzepatide/Retatrutide: Appetite-mediated weight loss through GLP-1 signaling. Much larger clinical evidence base but different mechanism (energy intake reduction vs direct lipolysis).

Research Protocols and Dosing

• Preclinical (murine): 500 mcg/kg/day IP for chronic obesity studies; effects typically observed within 2-4 weeks
• Preclinical (adipocyte cultures): 0.1-10 mcg/mL for lipolysis and lipogenesis assays
• Clinical trials: 250-500 mcg/day SC in human obesity studies
• Osteoarthritis research: Variable intra-articular doses depending on joint size and model
• Storage: Lyophilized at -20°C for long-term; reconstituted with bacteriostatic water at 4°C for up to 4 weeks

Safety Profile

AOD 9604 has one of the most favorable safety profiles among research peptides:

• No effect on IGF-1 levels — avoiding growth-related safety concerns
• No impairment of glucose tolerance — unlike full-length GH
• No effect on growth plate closure or linear growth
• No antibody formation detected in clinical trials
• TGA approval as complementary medicine ingredient (Australia)
• Phase 2 clinical trials confirmed safety and tolerability in human subjects
• GRAS (Generally Recognized as Safe) status in the United States for food use

Frequently Asked Questions

Does AOD 9604 increase growth hormone levels?

No. AOD 9604 is a fragment of GH that does not stimulate GH release or elevate IGF-1. It works directly on fat cells through the beta-3 adrenergic pathway, bypassing the GH-IGF axis entirely.

How does AOD 9604 compare to semaglutide for fat loss?

They work through completely different mechanisms. Semaglutide reduces appetite through GLP-1 receptor activation (less food intake). AOD 9604 directly stimulates fat cell lipolysis (fat breakdown). Semaglutide has far more clinical data supporting its efficacy.

Can AOD 9604 help with joint problems?

Preclinical research shows AOD 9604 has chondroprotective properties and may stimulate cartilage regeneration. It has TGA approval as a complementary medicine ingredient in Australia, partly based on this cartilage research.

Is AOD 9604 safe?

AOD 9604 has demonstrated a favorable safety profile in both preclinical studies and phase 2 human clinical trials. It does not elevate IGF-1, impair glucose tolerance, or promote growth — avoiding the major safety concerns associated with full-length GH.

Conclusion

AOD 9604 occupies a unique position in the fat loss peptide landscape — delivering the lipolytic benefits of growth hormone without its metabolic and growth-related risks. Its favorable safety profile, TGA regulatory recognition, and emerging cartilage regeneration applications make it a versatile research compound with multiple investigation avenues.

Explore AOD 9604 and our complete research peptide catalog. Visit the research hub for ongoing updates in metabolic peptide science.